<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511134</url>
  </required_header>
  <id_info>
    <org_study_id>0609001866</org_study_id>
    <secondary_id>ESRC099</secondary_id>
    <nct_id>NCT00511134</nct_id>
  </id_info>
  <brief_title>Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban</brief_title>
  <official_title>A Placebo-Controlled, Randomized Trial of Eszopiclone for the Treatment of Bupropion- and Abstinence-Related Insomnia During Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

      The primary objective of this study is to determine the efficacy of eszopiclone at treating
      sleep problems related to withdrawal from nicotine in healthy smokers attempting smoking
      cessation.

      Sleep disturbances are a significant problem for smokers who are trying to quit smoking.
      Smokers may be more likely to have sleep problems and both nicotine withdrawal and agents
      used to aid smoking cessation (e.g., pharmacotherapies) may disrupt sleep. Lunesta
      (eszopiclone) is a medication that has been approved by the FDA to treat insomnia.
      Eszopiclone's efficacy for treating insomnia makes it a promising agent for treating nicotine
      withdrawal-related symptoms of sleep disturbance.

      This study will be 7 weeks duration. All participants will begin taking Zyban at the
      beginning of week 1 and will be asked to try to quit smoking at the beginning of week 2.
      Participants will also begin to take Lunesta or matched placebo (3 mg qd x 6 weeks) on the
      target quit date at the beginning of week 2. All subjects will receive eight (8) weekly
      sessions of brief individual supportive smoking cessation counseling.

      Hypothesis:

      It is hypothesized that significantly fewer sleep problems will be reported by participants
      taking Lunesta as compared to placebo. Specifically, it is expected that participants taking
      Lunesta will report less difficulty falling and staying asleep, higher sleep quality, and
      less insomnia-related fatigue and distress than participants taking placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been terminated due low recruitment of participant population.
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Insomnia as Measured by the Insomnia Severity Index</measure>
    <time_frame>6 weeks after target smoking quit date</time_frame>
    <description>Insomnia Severity Index (ISI): 13-item self-report measure which examines symptoms of insomnia, consequences of insomnia, and subjective distress related to sleep problems. Subjects rate the symptoms and consequences of insomnia on a 5 point Likert scales. For example, subjects are asked to rate the severity of their insomnia (e.g., difficulty falling asleep from 0=none to 4=very severe). Scores on the first 7 items are summed for a total insomnia score ranging from 0-28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smoking Abstinence as Measured by Self Reported Smoking and Confirmed by CO Level</measure>
    <time_frame>6 weeks after target smoking quite date</time_frame>
    <description>Endpoint abstinence will be defined as 0 cigarettes over the seven days prior to the subject's Timeline Follow-Back evaluation at the end of week 7 (end of trial) and a Carbon Monoxide (CO) level ≤ 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Insomnia</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Zyban + Lunesta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zyban + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule</description>
    <arm_group_label>Zyban + Lunesta</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.</description>
    <arm_group_label>Zyban + Lunesta</arm_group_label>
    <arm_group_label>Zyban + Placebo</arm_group_label>
    <other_name>Zyban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are between ages 18-65 years old.

          -  Meet DSM-IV criteria for nicotine dependence.

          -  Smoke at least 15 cigarettes (3/4 pack) daily (averaged over 1 week, in the past 1
             month) and have an expired breath CO level &gt; 10.

          -  At the time of initial evaluation, are motivated to quit smoking in the next 30 days.

          -  Receive a score of ≥ 10 on the Insomnia Severity Index (ISI)

          -  Have the capacity to give informed consent, and are English-speaking.

        Exclusion Criteria:

          -  Are taking an over-the-counter or prescription medications that are known to affect
             sleep.

          -  Are taking medications contraindicated for use with eszopiclone or bupropion
             including: Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Nefazodone,
             Troleandomycin, Ritonavir, Nelfinavir, Trazodone, and Methadone.

          -  Are using any over-the-counter analgesics that contain caffeine.

          -  Have serious medical disorders that may make participation in the trial unsafe.

          -  Are physiologically dependent on and/or abusing alcohol or other drugs of abuse (e.g.,
             cocaine, opiates, benzodiazepines, etc.) in the past 6 months prior to randomization
             into the trial.

          -  Consume greater than 1 alcoholic beverage per day or greater than 7 alcoholic drinks
             per week.

          -  Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic
             disorder or post-traumatic stress disorder, or a current or past history bipolar
             disorder, schizophrenia, or anorexia or bulimia nervosa. Have a past history of major
             depression, with historical evidence of suicidal or homicidal behavior, or psychotic
             symptoms.

          -  Have the presence of suicidal or homicidal ideation, or significant impairment of
             social or occupational functioning, either at study baseline during the evaluation
             process, or during participation in the trial.

          -  Are from the same household as another study participant.

          -  A history of seizures of any etiology.

          -  A history of hypersensitivity to bupropion or Lunesta (eszopiclone).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea H. Weinberger, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <results_first_submitted>September 28, 2009</results_first_submitted>
  <results_first_submitted_qc>November 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2009</results_first_posted>
  <last_update_submitted>March 9, 2012</last_update_submitted>
  <last_update_submitted_qc>March 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Andrea H. Weinberger</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>nicotine dependence</keyword>
  <keyword>smoking</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>zyban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the Greater New Haven area and surrounding communities through targeted television, radio, and newspaper ads, fliers, and referrals from clinicians. Recruitment occurred between July of 2007 and October of 2008. Approximately 900 phone screens and 12 in-person screens were completed during the course of the study.</recruitment_details>
      <pre_assignment_details>Major reasons for exclusion at phone screen were report of no sleep problems, use of illegal substances, psychiatric or medical exclusions, and low smoking. Major reasons for exclusion during the in-person screening process included withdrawal of informed consent, alcohol or illicit drug use, and low smoking.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Zyban + Lunesta</title>
          <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and Eszopiclone (Lunesta; 3 mg qd x 6 weeks)</description>
        </group>
        <group group_id="P2">
          <title>Zyban + Placebo</title>
          <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and placebo pill (1 pill per day x 6 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zyban + Lunesta</title>
          <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and Eszopiclone (Lunesta; 3 mg qd x 6 weeks)</description>
        </group>
        <group group_id="B2">
          <title>Zyban + Placebo</title>
          <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and placebo pill (1 pill per day x 6 weeks)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Level of Insomnia as Measured by the Insomnia Severity Index</title>
        <description>Insomnia Severity Index (ISI): 13-item self-report measure which examines symptoms of insomnia, consequences of insomnia, and subjective distress related to sleep problems. Subjects rate the symptoms and consequences of insomnia on a 5 point Likert scales. For example, subjects are asked to rate the severity of their insomnia (e.g., difficulty falling asleep from 0=none to 4=very severe). Scores on the first 7 items are summed for a total insomnia score ranging from 0-28.</description>
        <time_frame>6 weeks after target smoking quit date</time_frame>
        <population>Baseline descriptive data was examined for the 4 participants. Outcome measures were available for 2 participants. Due to the small number of participants, statistical comparisons were not able to be performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Zyban + Lunesta</title>
            <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and Eszopiclone (Lunesta; 3 mg qd x 6 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Zyban + Placebo</title>
            <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and placebo pill (1 pill per day x 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Insomnia as Measured by the Insomnia Severity Index</title>
          <description>Insomnia Severity Index (ISI): 13-item self-report measure which examines symptoms of insomnia, consequences of insomnia, and subjective distress related to sleep problems. Subjects rate the symptoms and consequences of insomnia on a 5 point Likert scales. For example, subjects are asked to rate the severity of their insomnia (e.g., difficulty falling asleep from 0=none to 4=very severe). Scores on the first 7 items are summed for a total insomnia score ranging from 0-28.</description>
          <population>Baseline descriptive data was examined for the 4 participants. Outcome measures were available for 2 participants. Due to the small number of participants, statistical comparisons were not able to be performed.</population>
          <units>Units on a Scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="0" lower_limit="11" upper_limit="11"/>
                    <measurement group_id="O2" value="5" spread="0" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It was hypothesized that the Zyban+Lunesta group would report lower ISI scores at end of trial than the Zyban+Placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Descriptive data</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Abstinence as Measured by Self Reported Smoking and Confirmed by CO Level</title>
        <description>Endpoint abstinence will be defined as 0 cigarettes over the seven days prior to the subject’s Timeline Follow-Back evaluation at the end of week 7 (end of trial) and a Carbon Monoxide (CO) level ≤ 5.</description>
        <time_frame>6 weeks after target smoking quite date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zyban + Lunesta</title>
            <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and Eszopiclone (Lunesta; 3 mg qd x 6 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Zyban + Placebo</title>
            <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and placebo pill (1 pill per day x 6 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Abstinence as Measured by Self Reported Smoking and Confirmed by CO Level</title>
          <description>Endpoint abstinence will be defined as 0 cigarettes over the seven days prior to the subject’s Timeline Follow-Back evaluation at the end of week 7 (end of trial) and a Carbon Monoxide (CO) level ≤ 5.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>It is predicted that subjects taking eszopiclone will be more likely to report abstinence at trial endpoint than those taking placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <method_desc>Degrees of freedom=1</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 3 months</time_frame>
      <desc>weekly questionnaire</desc>
      <group_list>
        <group group_id="E1">
          <title>Zyban + Lunesta</title>
          <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and Eszopiclone (Lunesta; 3 mg qd x 6 weeks)</description>
        </group>
        <group group_id="E2">
          <title>Zyban + Placebo</title>
          <description>Bupropion SR (Zyban; 150 mg qd x 7 days, then 150 mg bid x 6 weeks) and placebo pill (1 pill per day x 6 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea H. Weinberger, Ph.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-974-7598</phone>
      <email>andrea.weinberger@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

